Rituximab therapy in refractory macrophage activation syndrome secondary to systemic lupus erythematosus
J. Bakshi,S. Hassan,David D'Cruz,A. Chan
DOI: https://doi.org/10.1177/0961203313504634
IF: 2.858
2013-09-06
Lupus
Abstract:Sir, Macrophage activation syndrome (MAS) is a lifethreatening condition characterised by high fever, pancytopenia, liver insufficiency and coagulopathy. Activation and uncontrolled proliferation of lymphocytes and well-differentiated macrophages cause widespread haemophagocytosis and cytokine overproduction. Systemic autoimmune disease has been reported to be the underlying disorder in 2 5% of cases of MAS, and in adults systemic lupus erythematosus (SLE) is by far the most common accounting for about 60% of cases. Rituximab use has been mainly reported in MAS secondary to Epstein Barr virus (EBV) infection but not SLE. A 45-year-old Jamaican male with SLE presented with a one-month history of fever and malaise. Two months prior to presentation he had been newly diagnosed with SLE after presenting with a symmetrical polyarthritis, oral ulceration, positive ANA (1:640 homogenous), dsDNA 40U/mL, C3 0.52 g/ L (range 0.65 1.65), C4 0.03 g/L (range 0.16 0.6), ESR 70mm/h and CRP 12mg/L (meeting the American College of Rheumatology classification criteria). There was no renal involvement at diagnosis. Low-dose prednisolone and hydroxychloroquine were commenced with an improvement to his polyarthritis and his SLEDAI score was 4. Clinical examination on admission was unremarkable other than a tachycardia (100 beats/ minute) and a fever of 38.6 C. Chest x-ray and electrocardiography were normal. Urine dipstick showed protein (1þ) and blood (3þ). Laboratory investigations on admission (day 1) are shown in Table 1. Treatment with amoxicillin clavulanic acid was commenced for a possible respiratory tract infection. Due to nausea, intravenous (IV) hydrocortisone instead of oral corticosteroid was commenced to cover for a SLE flare. He continued to have fevers >40 C and developed a neutropenia (0.6 10/L) requiring antibiotic cover for potential neutropenic sepsis. CT chest/abdomen/pelvis showed no collections or hepato-splenomegally. The patient became acutely unwell developing disseminated intravascular coagulation (DIC) at day 14 of admission (Table 1). His anti-dsDNA (627 u/mL) and complements were low (C3 0.44 and C4 0. 06 g/L). Magnetic resonance imaging of the brain showed multiple small haemorrhages. Treatment was switched to meropenem, antiviral and anti-fungal to cover possible invasive opportunistic infections and blood products were given. Despite 7 days of the above regimen, CRP (280mg/L) and ESR (132mm/h) remained elevated with ongoing pyrexias and cytopenias. A renal biopsy was considered but deemed unsafe due to the patient’s severe DIC. Repeated blood and urine cultures and a thorough infection screen including a viral panel for Herpes Simplex, Herpes Zoster, EBV, cytomegalovirus, Hepatitis B and C, HIV, Coxsackie and Parvovirus B19 viruses were negative. Elispot was negative for tuberculosis. Echocardiogram and abdominal ultrasound were normal. CSF protein was elevated at 1.34 g/L (0.12 0.6) and CSF viral and bacterial cultures were negative. Serum ferritin was >2000mg/dL, raised triglycerides (300mg/dL) and a low fibrinogen (100mg/dL). Bone marrow aspiration showed the presence of histiocytes (Figure 1). MAS secondary to acute SLE in the absence of identifiable infection was established based on laboratory, clinical and bone marrow findings. Methylprednisolone 1 g/day for three days followed by 1mg/kg/day orally and IVIG 2 g/kg over five days were initiated. Despite this regimen his counts remained low with significant renal dysfunction. Due to ongoing cytopenias and renal impairment treatment with immunosuppressive drugs such as cyclophosphamide or cyclosporine were not given due to potential risks. A decision to treat with rituximab (1 g two weeks apart) was reached. Within seven days from the first infusion the platelet and neutrophil counts recovered to normal (Table 1). After two infusions the patient improved clinically with no further fevers, the cytopenias reversing concomitantly and the inflammatory indices and ferritin levels all gradually returned to normal. Mycophenolate mofetil 2 g/day as maintenance therapy was commenced. Correspondence to: Jyoti Bakshi, Rheumatology department, High Wycombe Hospital, Queen Alexandra Road, High Wycombe, Buckinghamshire, HP11 2TT, UK. Email: jb101@doctors.org.uk Received 7 April 2013; accepted 19 August 2013